Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 15/20 | 0.62 |
| ▸ | ESRRB | O95718 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESRRG | P62508 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | VHL | P40337 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649119 | 1.00 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648125 | 0.95 | ESRRA (0.63) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648126 | 0.95 | ESRRA (0.63) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648910 | 0.94 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650091 | 0.94 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648909 | 0.94 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL651256 | 0.94 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650136 | 0.93 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650137 | 0.93 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648616 | 0.88 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119669-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | claimed |
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | claimed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| EP-2536716-B1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2582674-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | GAUL MICHAEL (US) | 2012-05-03 | — | — | US | disclosed |
| US-8119669-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | disclosed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.